Viscofan BioEngineering
Develops and manufactures fibrillary collagen bioinks (Fibercoll-Flex®) for 3D bioprinting of tissue models and scaffolds, enabling high-fidelity cell encapsulation and robust 3D structures without methacrylation curing.
- CEO / Founder
- Lluis Quintana Frigola
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $2.06M
- Latest Round
- Grant
- Key Investors
- European Union
Technology & Products
Key Products
Fibercoll-Flex® bioinks (Fibercoll-Flex-A®, Fibercoll-Flex-N®); Collagen Cell Carrier®; Bovine Soluble Collagen; Collagen Bio Tubes; Viscolma® Collagen Suspension; Collagen Gel™
Technological Advantage
Proprietary collagen extraction and processing technologies (standardized per ASTM F2212-02) ensure batch-to-batch purity and biocompatibility; industrial-scale production capabilities for both research and medical grade materials.
Differentiation
Value Proposition
Provides ultrapure, biocompatible collagen bioinks that reduce development time for tissue models by enabling easy, reliable 3D printing with high cell viability and mechanical strength, accelerating bench-to-bedside transfer in regenerative medicine.
How They Differentiate
Fibercoll-Flex® bioinks offer 3D printing with pure fibrillary collagen (no additives) vs. competitors' cross-linked or composite materials; enables high cell viability (>90% in studies) and shape fidelity for complex scaffolds, supported by industrial manufacturing scale.
Market & Competition
Target Customers
Biomedical researchers, tissue engineering labs, regenerative medicine companies, and medical device developers
Industry Verticals
Biomedical Research; Tissue Engineering; Regenerative Medicine; Medical Devices
Competitors
Collagen Solutions; Acelity; Baxter International Inc.
Growth & Milestones
Growth Metrics
Attending Supplyside West 2024 conference as exhibitor; positioned to grow significantly in revenue, EBITDA, and net profit in 2024 per Viscofan LinkedIn; founded in 2007; operates in regenerative medicine and nutritional applications
Major Milestones
Launched in 2008 as a business unit of Viscofan Group; Introduced Fibercoll-Flex® bioinks for 3D bioprinting; Partnered with Avantor for US distribution in 2023; Coordinates TriAnkle EU project for additive manufacturing of personalized implants
Notable Customers
Asemblis